Stock Analysis, Dividends, Split History

EQT / EQT Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)12,418.56
Enterprise Value ($M)24,776.78
Book Value ($M)11,679.28
Book Value / Share44.24
Price / Book1.06
NCAV ($M)-10,479.80
NCAV / Share-39.70
Price / NCAV-1.19
Share Statistics
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 264,473,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.10
Return on Assets (ROA)0.12
Return on Equity (ROE)0.32
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio0.76
Income Statement (mra) ($M)
Gas Gathering Transportation Marketing And Processing Revenue336,676,000.00
Variable Interest Entity Activity Between VIE And Entity Revenues0.00
Results Of Operations Sales Revenue To Unaffiliated Enterprises0.00
Oil And Gas Revenue3,378,015,000.00
Revenues Excluding Gain Losson Derivatives0.00
Oil And Gas Sales Revenue2,651,318,000.00
Operating Income932.98
Net Income1,858.14
Earnings Per Share Basic8.05
Earnings Per Share Diluted8.04
Cash Flow Statement (mra) ($M)
Cash From Operations1,637.70
Cash from Investing-4,127.07
Cash from Financing-4,127.07
Identifiers and Descriptors
Central Index Key (CIK)33213
Related CUSIPS
26884L959 026884L10 26884L909 294549100

Split History

Stock splits are used by EQT Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Chesapeake Energy Stock Remains High-Risk, High-Reward

8h investorplace
Over the past year or so, I’ve recommended Chesapeake Energy (NYSE:CHK) as a high-risk, high-reward play. I even briefly owned Chesapeake Energy stock last year. Whether those calls were correct comes down mostly to timing: CHK stock continues to trade sideways, dipping below $3 earlier this year and climbing above $5 in July before yet another pullback to about $4. (29-0)

AltaGas: Abandoning Canada, Will The Company Win Over U.S. Investors?

2018-09-17 seekingalpha
AltaGas has been consistently investing in U.S. projects over Canadian ones. Recent divestitures to fund the U.S. based WGL Holdings acquisition have tilted Canadian. (10-0)

10 Oil Stocks That Are Worth a Second Look

2018-09-05 investorplace
The last few weeks have been tricky ones for energy investors. Some oil stocks have struggled, while others have managed to rally. The market has taken each of these names on a case-by-case basis. (8-1)

Tracking George Soros's Portfolio - Q2 2018 Update

2018-09-02 seekingalpha
Soros' 13F portfolio value increased from $6.16B to $6.25B this quarter. The number of positions decreased from 219 to 203. (138-9)

Top Research Reports for Visa, PNC Financial & SAP

2018-08-29 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa (V), PNC Financial Services Group (PNC) and SAP SE (SAP). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (17-0)

CUSIP: 26884L109